Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astria Therapeutics, Inc. - Common Stock
(NQ:
ATXS
)
7.060
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
7.060
Bid (Size)
6.660 (1)
Ask (Size)
8.270 (1)
Prev. Close
7.060
Today's Range
7.060 - 7.060
52wk Range
6.640 - 16.90
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Performance
YTD
-21.29%
-21.29%
1 Month
-6.74%
-6.74%
3 Month
-22.93%
-22.93%
6 Month
-39.55%
-39.55%
1 Year
-49.39%
-49.39%
More News
Read More
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session
February 03, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
January 23, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE
January 13, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 24, 2024
Via
Benzinga
Limoneira And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
December 24, 2024
Via
Benzinga
Arm Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
December 23, 2024
Via
Benzinga
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
December 23, 2024
Via
Benzinga
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
December 11, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
December 10, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 14, 2024
Via
Benzinga
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 13, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
November 13, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
October 30, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
October 21, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
October 16, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
September 30, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Global Angioedema Forum
September 27, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
September 19, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024
From
Astria Therapeutics
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.